Close
  Indian J Med Microbiol
 

Figure 1: Kaplan–Meier estimates of progression-free survival (in months) of the patients (n = 107) treated with modified epirubicin, cisplatin, and 5-FU regimen

Figure 1: Kaplan–Meier estimates of progression-free survival (in months) of the patients (<b>n</b> = 107) treated with modified epirubicin, cisplatin, and 5-FU regimen